Additional contraceptive measures for women taking Mounjaro and using birth control pills are recommended by the European Medicines Agency (EMA).
The focus is on the possible effect of the active substance tirzepatide on the reliability of birth control pills and, consequently, the need for additional protection of women who can become pregnant.
According to the EMA announcement, there is limited information on how tirzepatide affects the pharmacokinetics and efficacy of oral contraceptives in women with obesity, overweight or type 2 diabetes.
For this reason, women who use a contraceptive pill and start treatment with Mounjaro are advised to take additional contraceptive measures.
What EMA recommends
The new Recommendation provides for two options.
The first is the addition of a barrier contraceptive method, such as a condom, for four weeks after starting treatment with tirzepatide and for another four weeks after each dose increase.
The second option is to switch to a non-oral method of contraception, after consultation with the attending physician.
The warning does not mean that Mounjaro has been shown to cause the failure of birth control pills.
It reflects the need for proactive protection, as the available data is not sufficient to rule out a potential impact on their effectiveness.
Why there is concern
Tirzepatide slows down the emptying of the stomach, which can affect the rate of absorption of certain medications taken orally.
This property is one of the reasons why its possible interaction with birth control pills is being considered.
The concern is particularly concerned with the period of initiation of treatment and the periods of dose increase, during which women are asked to apply the additional protection measures.
Informing healthcare professionals
The CHMP has adopted a special Immediate Information Letter to Healthcare Professionals (DHPC), which will be distributed by the company that holds the marketing authorisation following the European Commission's decision.
The update will also be published on the EMA's website and in the national registers of the Member States of the European Union.
Mounjaro is used, in combination with proper diet and physical activity, to treat adults with poorly controlled type 2 diabetes mellitus.
It is also approved for weight management in people with obesity or overweight accompanied by weight-related health problems.
Women taking the drug and using contraceptive pills are asked to discuss with their doctor or pharmacist the appropriate method of contraception, without interrupting or modifying their medication on their own.
